If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

New PREtec Products Announced

28 Sep 2023 07:00

RNS Number : 8895N
Plant Health Care PLC
28 September 2023
 

28 September 2023

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

New PREtec Products Announced

 

Brazilian Launch of MOSHY™ and TEIKKO™ planned

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce two new brands - MOSHY and TEIKKO - derived from the Company's PREtec technology platform (Vaccines for PlantsTM) for launch in Brazil for the 2024 soybean growing season.

 

Highlights:

 

· MOSHY (PHC25279) is a foliar product registered in Brazil to control foliar diseases in coffee and sugar cane.

· TEIKKO (PHC68949) is a seed treatment to control harmful soil nematodes in soybean fields. This is expected to be registered in Brazil before the end of 2023.

· MOSHY and TEIKKO add to the portfolio of Plant Health Care products available to growers in Brazil.

· Discussions with potential Brazilian distributors of MOSHY and TEIKKO are ongoing.

· For the six months ended 30 June 2023, revenue in Brazil was up 48%, driven by in-market demand for H2Copla® (Harpinαβ) and Saori® (PREtec).

 

MOSHY and TEIKKO provide specific benefits for growers of improved disease and nematode control, plant health and yield.

 

MOSHY helps control a broad spectrum of plant diseases when used as part of an integrated disease control program. MOSHY was shown to reduce the incidence and severity of sugar cane orange rust and coffee leaf rust leading to significant increases in yield. Brazil is the world's largest producer of sugar cane and coffee. As part of Plant Health Care's continued investment in Brazilian agriculture, additional crop specific, plant pathogen claims will be added to the MOSHY product label, allowing use on a wider range of crops.

 

TEIKKO is a novel product that amplifies a plant's natural defense pathways to provide protection against plant parasitic nematodes which damage plant roots and limit crop yield. TEIKKO was submitted as a seed treatment for the control of root-lesion nematode (Pratylenchus brachyurus) in soybean. Research carried out during the 2021/22 and 2022/23 soybean crop seasons showed that TEIKKO controlled Pratylenchus brachyurus in soybeans, with similar or superior performance when compared to standard market treatments. For the 2023/24 season, the soybean harvested area in Brazil is forecast to be 45.6 million hectares. Additional crops and nematode species will be added to the TEIKKO product label further expanding its potential use.

 

Both products are based on the Company's innovative PREtec technology platform. Derived from natural proteins, PREtec is an environmentally friendly technology which stimulates plant defense and pathogen resistance mechanisms within plants, resulting in improved crop growth and quality along with the ability to withstand a variety of abiotic stresses. 

 

As well as launching new products in its existing markets, Plant Health Care continues to expand into new markets around the world and is growing its relationships with major global distribution partners. As a result, the Company is on track to achieve revenue of $30 million by 2025.

 

Jeff Tweedy, CEO of Plant Health Care, said: ‟Plant Health Care continues to scale our global business with the addition of TEIKKO and MOSHY to the Brazil product line which includes H2Copla and Saori. Plant Health Care's biological products have earned the reputation of contributing to sustainable agriculture while increasing yields, controlling diseases, and generating a positive ROI for growers. We expect MOSHY and TEIKKO to be novel biological products that will deliver control of nematodes and diseases in critical Brazil crops. These new product launches are key steps for Plant Health Care in meeting our $30 million revenue target by 2025."

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

+1 919 926 1600

Cavendish Securities plc - Nomad & Broker Neil McDonald / Pete Lynch

+44 (0) 131 220 9771

SEC Newgate - Financial Communications Robin Tozer / Harry Handyside / George Esmond

+44 (0)7540 106 366 phc@secnewgate.co.uk

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PRLBUGDCISDDGXR
Date   Source Headline
29th Aug 200810:37 amRNSNotice of Results
15th Aug 200812:36 pmRNSHolding(s) in Company
1st Aug 20081:08 pmRNSTotal Voting Rights
7th Jul 200812:21 pmRNSHolding(s) in Company
4th Jul 20087:00 amRNSProduct Update
3rd Jul 20087:00 amRNSCleantech Index
2nd Jul 200812:07 pmRNSStock Award
1st Jul 200811:49 amRNSTotal Voting Rights
17th Jun 20085:36 pmRNSAdditional Listing
17th Jun 20083:47 pmRNSNotification of Shareholding
13th Jun 20082:07 pmRNSHolding(s) in Company
12th Jun 20087:00 amRNSField Trials
6th Jun 200812:59 pmRNSResult of Annual General Meet
6th Jun 20087:00 amRNSAGM Statement and Trading Upd
3rd Jun 20087:30 amRNSField Trials
2nd Jun 20089:50 amRNSTotal Voting Rights
13th May 200812:41 pmRNSDirectors' dealings and addit
1st May 20082:39 pmRNSAdditional Listing
30th Apr 20086:11 pmRNSAnnual Report and Accounts
30th Apr 200811:24 amRNSTotal Voting Rights
28th Apr 20088:09 amRNSNew Trials
14th Apr 20085:39 pmRNSDirector/PDMR Shareholding
2nd Apr 20086:18 pmRNSDirector/PDMR Shareholding
1st Apr 20087:01 amRNSDirectorate Change
1st Apr 20087:01 amRNSTotal Voting Rights
31st Mar 20087:02 amRNSFinal Results
12th Mar 20084:40 pmRNSAdditional Listing
29th Feb 20084:59 pmRNSTotal Voting Rights
21st Feb 20087:01 amRNSStatement re Monsanto
18th Feb 20088:00 amRNSASA Partnership
12th Feb 20085:14 pmRNSAdditional Listing
31st Jan 20084:03 pmRNSTotal Voting Rights
21st Jan 20087:01 amRNSRe Agreement
21st Jan 20087:01 amRNSProduct Update
21st Jan 20087:01 amRNSTrading Statement
14th Jan 200811:57 amRNSNotification of Shareholding
9th Jan 20089:00 amRNSField Trial Update
31st Dec 200712:51 pmRNSTotal Voting Rights
19th Dec 20079:00 amRNSNotification of Shareholding
3rd Dec 20073:00 pmRNSTotal Voting Rights
20th Nov 20079:15 amRNSAdditional Listing
1st Nov 200712:16 pmRNSTotal Voting Rights
24th Oct 20076:13 pmRNSStock Award
22nd Oct 200710:35 amRNSNotification of Shareholding
5th Oct 20073:56 pmRNSNotification of Shareholding
2nd Oct 20074:46 pmRNSNotification of Shareholding
2nd Oct 200712:59 pmRNSTotal Voting Rights
1st Oct 20075:54 pmRNSNotification of Shareholding
1st Oct 20075:51 pmRNSNotification of Shareholding
1st Oct 20073:22 pmRNSDoc re. Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.